Diligence memo · auto-generated · as of July 2, 2026
Mercury Bio, Inc.
Mercury Bio, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Mercury Bio, Inc. operates in Biotechnology, based in SANTA FE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Mercury Bio, Inc. has raised $3.9M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.4M on 2025-09-30.
Most recent recorded round closed around 2025-09-30.
Valuation (modeled)modeled
Provath models Mercury Bio, Inc. at approximately $5.8M (range $1.7M–$11M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.26× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (126% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 15.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 39% of Biotechnology peers (4293 compared).
Modeled value ranks above 12% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.